IDEAYA Biosciences completed an NDA submission for darovasertib combined with crizotinib to treat metastatic uveal melanoma, supported by positive clinical trial data presented at ESMO 2026 showing benefits regardless of HLA status. The company also reported encouraging results for IDE849 in relapsed small cell lung cancer and neuroendocrine carcinomas, with further data expected soon. IDEAYA plans to advance multiple clinical trials and collaborations, maintaining a strong cash position of $1.15 billion to fund operations into 2030. This positions darovasertib as a potential foundational therapy for uveal melanoma and supports ongoing development of targeted oncology treatments.
IDEAYA Biosciences financial results and business update provide context for readers. For those following the health sector, 70 of 150 priced US stocks rose and 69 fell today on Pluang. Notable movers include NUWE at USD 5.01 with a -3.28% change, COGT at USD 30.58 up 2.86%, and ACB at USD 4.34 up 2.84%, as of Nov 03, 2026 17:51 WIB.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
